Tags : Clinical Trial

Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in

Shots: The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation Strata Oncology will identify patients to be considered for enrollment into Mirati’s P-I/II study. The Strata Trial provides tumor molecular profiling for patients with advanced […]Read More

MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for

Shots: Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda, to evaluate its safety and efficacy in solid tumors (i,e., NSCLC, melanoma, Urothelial cancer, Liposarcoma, MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment) The companies will […]Read More

Hope Biosciences Reports its Third US FDA’s Approval for Clinical

Shots:Shots: The company will conduct its third study in collaboration with ADH at River Oaks Hospital and Clinics to determine the role of its HB-adMSCs in decreasing the severity of illness in patients with COVID-19 The P-II study will assess HB-adMSCs vs PBO in patients receiving hydroxychloroquine and azithromycin and not receiving this combination therapy. […]Read More

BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate

Shots: NeoImmuneTech to sponsor the trial and BMS will supply Opdivo (nivolumab) for the use in the trial. Additionally, under Master Clinical Trial Collaboration Agreement, the first study will be focusing on gastric/GEJ/EAC cancers and the companies can evaluate additional combination trials in the future The goal of the collaboration is to evaluate preliminary anti-tumor […]Read More

Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292

Shots: The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician’s choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have received no prior systemic therapy for metastatic disease The study will have efficacy endpoints as progression-free survival (PFS), treatment failure-free survival (TFFS), overall survival (OS), […]Read More

Genentech Signs a Clinical Trial Collaboration with Arcus for Colorectal

Shots: The companies collaborate for the evaluation of novel candidates with Arcus’s AB928 utilizing the MORPHEUS P-Ib/II platform with upfront randomization versus control groups in two studies. The companies will supply its anti-cancer agents and will jointly find the studies The two studies are: The first study will assess AB928 + Tecentriq + regorafenib, Tecentriq […]Read More